09.10.2013 14:44:43

OncoMed Gets First US Patent On MAbTrap Antibody Display Technology

(RTTNews) - OncoMed Pharmaceuticals, Inc. (OMED), Wednesday said that its MAbTrap antibody display technology, received the first U.S. patent from the United States Patent and Trademark Office. MAbTrap enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity.

OncoMed said it has used the patented technology to find and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.

The new patent relates to methods of producing libraries of cells that express membrane-bound antibodies or other specific binding agents on their surface, and methods of identifying the cells in such libraries that express an antibody or other agent having the desired binding characteristics. The patented methods include novel mammalian cell display methods. Related patent applications are currently pending in the U.S., Europe, Japan, China, and a number of other countries worldwide.

Nachrichten zu OncoMed Pharmaceuticals Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu OncoMed Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!